Four-dimensional naturally reductive pseudo-Riemannian spaces

The classification of 4-dimensional naturally reductive pseudo-Riemannian spaces is given. This classification comprises symmetric spaces, the product of 3-dimensional naturally reductive spaces with the real line and new families of indecomposable manifolds which are studied at the end of the article. The oscillator group is also analyzed from the point of view of this classification

Covariant un-reduction for curve matching

The process of un-reduction, a sort of reversal of reduction by the Lie group symmetries of a variational problem, is explored in the setting of field theories. This process is applied to the problem of curve matching in the plane, when the curves depend on more than one independent variable. This situation occurs in a variety of instances such as matching of surfaces or comparison of evolution between species. A discussion of the appropriate Lagrangian involved in the variational principle is given, as well as some initial numerical investigations.Comment: Conference paper for MFCA201

Reduction in principal fiber bundles: covariant Euler-Poincare equations

Let $\pi:P\to M^n$ be a principal G-bundle, and let ${\mathcal{L}}: J^1P \to\Lambda^n(M)$ be a G-invariant Lagrangian density. We obtain the Euler-Poincare equations for the reduced Lagrangian l defined on ${\mathcal C}(P)$, the bundle of connections on P

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation

Reduction in principal fiber bundles: covariant Euler-Poincare equations

Let $\pi:P\to M^n$ be a principal G-bundle, and let ${\mathcal{L}}: J^1P \to\Lambda^n(M)$ be a G-invariant Lagrangian density. We obtain the Euler-Poincare equations for the reduced Lagrangian l defined on ${\mathcal C}(P)$, the bundle of connections on P